tirzepatide lawsuit 2025 Lilly seeks to intervene in compounded FDA Allows Compounded Tirzepatide During

Step 2: Online Consultation Consult with a licensed professional via telehealth

The SELECT trial, published in The Lancet (October 22, 2025), provides a landmark analysis confirming that the cardioprotective benefits of semaglutide extend beyond weight loss alone. The SELECT Trial: Study Overview The SELECT trial (NCT03574597) enrolled 17,604 participants aged 45 years and above across 41 countries and 804 sites

Your provider may need to adjust doses of other diabetes medications when initiating or escalating GLP-1 therapy

10.1371/journal.ppat.1011571 33 ChenY.ThaiP.ZhaoY.-H.HoY.-S.DesouzaM

For more than a decade , Endocrine News talks to editors from Endocrine Society publications to unearth the top endocrine discoveries of the past year